Literature DB >> 11123059

Macrophagic myofasciitis.

P Cherin1, R K Gherardi.   

Abstract

A most unusual inflammatory myopathy, called macrophagic myofasciitis, first described by the Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD), a specific branch of the Association Française contre les Myopathies was recorded with an increasing frequency from 1993 in the main French myopathologic centers. In October 1999, 65 macrophagic myofasciitis cases were recorded since our first description. We described the characteristics of the first 22 patients. The 22 patients (sex-ratio M/F, 1:3) were referred with the presumptive diagnosis of polymyositis (11), polymyalgia rheumatica (five), mitochondrial cytopathy (four), and congenital myopathy or muscle dystrophy (one each). Symptoms included myalgias (91%), arthralgias (68%), marked asthenia (55%), muscle weakness (45%), and fever (32%). Abnormal laboratory findings included elevated CK levels (50%), markedly increased ESR (37%), and myopathic EMG (35%). Muscle biopsy showed a unique myopathologic pattern characterized by 1) centripetal infiltration of epimysium, perimysium, and perifascicular endomysium by sheets of large cells of the monocyte/macrophage lineage (CD68+, CD1a-, S100-), with a PAS-positive content; 2) absence of necrosis, of both epithelioid and giant cells, and of mitotic figures; 3) presence of occasional CD8+ T-cells; 3) inconspicuous muscle fibre damage. The picture was easily distinguishable from sarcoid myopathy and fasciitis-panniculitis syndromes. The infectious diseases could not be documented in our patients. Patients improved under steroid therapy, associated or not with nonspecific antibiotic therapy. The authors discuss the main etiologic hypothesis of the macrophagic myofasciitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123059     DOI: 10.1007/s11926-000-0079-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  27 in total

Review 1.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

2.  Differential release of interleukin (IL)-1 alpha, IL-1 beta, and IL-6 from normal human monocytes stimulated with a virulent and an avirulent isogenic variant of Mycobacterium avium-intracellulare complex.

Authors:  M B Michelini-Norris; D K Blanchard; C A Pearson; J Y Djeu
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

Review 3.  [Non-infectious inflammatory fasciitis: a borderline syndrome].

Authors:  E Hachulla; A Janin
Journal:  Rev Med Interne       Date:  1995       Impact factor: 0.728

4.  Toxic epidemic syndrome, Spain, 1981. Toxic Epidemic Syndrome Study Group.

Authors: 
Journal:  Lancet       Date:  1982-09-25       Impact factor: 79.321

5.  Disseminated histiocytosis and intestinal malakoplakia. Occurrence due to Mycobacterium intracellulare infection.

Authors:  D Miranda; J C Vuletin; S L Kauffman
Journal:  Arch Pathol Lab Med       Date:  1979-06       Impact factor: 5.534

6.  Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome.

Authors:  A N Mayeno; L M Benson; S Naylor; M Colberg-Beers; J T Puchalski; G J Gleich
Journal:  Chem Res Toxicol       Date:  1995 Oct-Nov       Impact factor: 3.739

7.  Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation.

Authors:  D M Frucht; S M Holland
Journal:  J Immunol       Date:  1996-07-01       Impact factor: 5.422

8.  Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma.

Authors:  A Alonso-Ruiz; A C Zea-Mendoza; J M Salazar-Vallinas; A Rocamora-Ripoll; J Beltrán-Gutiérrez
Journal:  Semin Arthritis Rheum       Date:  1986-02       Impact factor: 5.532

9.  L-tryptophan and eosinophilia-myalgia syndrome in New Mexico.

Authors:  M Eidson; R M Philen; C M Sewell; R Voorhees; E M Kilbourne
Journal:  Lancet       Date:  1990-03-17       Impact factor: 79.321

Review 10.  Histiocytes and histiocytosis.

Authors:  M J Cline
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

View more
  5 in total

Review 1.  Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease.

Authors:  Eitan Israeli; Nancy Agmon-Levin; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

2.  Bordetella Colonization Factor A (BcfA) Elicits Protective Immunity against Bordetella bronchiseptica in the Absence of an Additional Adjuvant.

Authors:  Kacy S Yount; Jamie Jennings-Gee; Kyle Caution; Audra R Fullen; Kara N Corps; Sally Quataert; Rajendar Deora; Purnima Dubey
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

3.  Macrophagic myofascitis associated with rheumatoid arthritis.

Authors:  Kiyoshi Migita; Ruka Ueda-Nakata; Tomoko Masuda; Taichiro Miyashita; Tomohiro Koga; Yasumori Izumi; Katsuhiro Ichinose; Hironori Ezaki; Masahiro Ito; Masakatsu Motomura; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2009-06-19       Impact factor: 2.631

4.  Polyglandular autoimmunity with macrophagic myofasciitis.

Authors:  Brett J Theeler; Novae B Simper; John P Ney
Journal:  Clin Rheumatol       Date:  2008-01-08       Impact factor: 2.980

Review 5.  Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.

Authors:  Nikolai Petrovsky
Journal:  Drug Saf       Date:  2015-11       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.